Physician profile
Deepak Patel
NPI 1972551984
$8,407.33
in general payments reported to CMS, 2019-2025
33 companies · $805 in 2025
The $805 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,286 · 2020: $1,119 · 2021: $934 · 2022: $543 · 2023: $862 · 2024: $1,858 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,546 · Travel and Lodging: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.42 |
| Travel and Lodging | $979.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,712.41 | 2019-2020 | |
| Abbott Laboratories | $1,163.40 | 2019-2024 | Aveir |
| Novartis Pharmaceuticals Corporation | $916.55 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $613.07 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $379.72 | 2021-2024 | Verquvo |
| Pfizer INC. | $358.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $318.58 | 2020-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.17 | 2020-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $202.86 | 2019-2024 | |
| Inspire Medical Systems, INC. | $188.58 | 2025 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $162.97 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $136.57 | 2019-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $124.18 | 2024 | Micra |
| Kiniksa Pharmaceuticals, Ltd. | $116.45 | 2023 | Arcalyst |
| Ge Healthcare | $91.27 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $77.98 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $73.93 | 2024 | Arcalyst |
| Novo Nordisk INC | $69.71 | 2024-2025 | Wegovy, Ozempic |
| Boston Scientific Corporation | $68.64 | 2024-2025 | General - Therapies, Watchman Flx |
| Arbor Pharmaceuticals, INC. | $66.34 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $37.61 | 2024 | |
| Cashflow Solutions, LLC | $36.20 | 2022 | |
| Dexcom, INC. | $29.18 | 2023 | Dexcom G6 Transmitter |
| Lexicon Pharmaceuticals, INC. | $21.43 | 2024 | |
| Amgen INC. | $18.96 | 2025 | Repatha |
| Cvrx, INC. | $18.87 | 2024 | Barostim Neo System |
| Esperion Therapeutics, INC. | $18.82 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $18.81 | 2024 | Arexvy, Trelegy Ellipta |
| Angiodynamics, INC. | $16.74 | 2022 | |
| Atricure, INC. | $16.27 | 2022 | |
| Abiomed | $15.81 | 2021 | |
| Chiesi USA, INC. | $15.42 | 2021 | |
| Althera Pharmaceuticals LLC | $9.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.